Literature DB >> 15613213

Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.

J Castillo1, P Muñoz, V Guitera, J Pascual.   

Abstract

BACKGROUND AND OBJECTIVES: Although chronic daily headache, mainly transformed migraine, is an important reason for consultation in headache clinics, its actual prevalence is unknown. This study analyzes the prevalence of the different types of chronic daily headache in an unselected population.
METHODS: A questionnaire exploring headache frequency was distributed to 2252 unselected subjects. Those having headache 10 or more days per month were given a headache diary and were seen by a neurologist who classified their headaches. The varieties of chronic daily headache were classified according to the second revision of IHS criteria proposed by Silberstein et al published in Neurology 1996;47:871.
RESULTS: The questionnaire was returned by 1883 subjects (83.5%). One hundred thirty-five admitted to headache 10 or more days per month. Chronic daily headache criteria were fulfilled by 89 individuals (4.7%). Eighty were women. Forty-two (47.2% of subjects with chronic daily headache and 2.2% of all subjects) had chronic tension-type headache. Analgesic overuse was found in 8 (17%). Transformed migraine was diagnosed in 45 (50.6% of subjects with chronic daily headache and 2.4% of all subjects). Fourteen (31.1%) individuals with this form of chronic daily headache overused ergots or analgesics. The remaining 2 cases in this series met the criteria of new daily persistent headache. No one was diagnosed as having hemicrania continua.
CONCLUSIONS: Almost 5% of the general population (9% of women) suffers from chronic daily headache, the proportion of chronic tension-type headache and transformed migraine being quite similar. Less than one third overuse analgesics. The prevalence of chronic daily headache subtypes shown here differs from data obtained from headache clinics, emphasizing that caution is needed in extrapolating data from specialized units to the general population.

Entities:  

Mesh:

Year:  1999        PMID: 15613213     DOI: 10.1046/j.1526-4610.1999.3903190.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  155 in total

Review 1.  Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans.

Authors:  Z Katsarava; H C Diener; V Limmroth
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Headache.

Authors:  T J Steiner; Manuela Fontebasso
Journal:  BMJ       Date:  2002-10-19

Review 3.  Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis.

Authors:  Vincenzo Guidetti; Federica Galli
Journal:  Curr Pain Headache Rep       Date:  2002-12

Review 4.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 5.  Chronic daily headache.

Authors:  Peter J Goadsby; Christopher Boes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 6.  [Gordian knot: medication overuse headache].

Authors:  Z Katsarava; G Fritsche
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 7.  Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Pasquale Persico; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

8.  OnabotulinumtoxinA in pediatric chronic daily headache.

Authors:  Marielle Kabbouche; Hope O'Brien; Andrew D Hershey
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

9.  Chronic Daily Headache.

Authors:  James R. Couch
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

Review 10.  Headache in primary care: how important is diagnosis to management?

Authors:  Norma O'Flynn; Leone Ridsdale
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.